Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this ...

Approval makes Gomekli the first treatment to be approved for both adults and pediatric patients for neurofibromatosis type 1 ...

Shares of SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) climbed 2.7%, building on a previous gain of 2%, following the FDA ...

Travere’s stock price climbed by 14% following the announcement it will seek an FDA label expansion for Filspari.

Indivior PLC (Nasdaq/LSE: INDV) provides the following update regarding its PDUFA action date for label changes (rapid initiation protocol and alternative injection sites) for SUBLOCADE® ...

The Food and Drug Administration (FDA) approved a new drug to treat a disorder causing the growth of non-cancerous tumors on ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

Tirzepatide, found in Mounjaro and Zepbound, mimics both GIP and GLP-1 hormones to activate insulin production. Semaglutide, ...

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...

Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...